問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taichung Veterans General Hospital

Link to Hospital

  • 1,624

    Total Beds

  • 934

    Total Doctors

  • tcvghcrc@vghtc.gov.tw
  • Clinical Research Center
  • 04-23592525#4780
  • 407Taichung CityTaichung Xitun1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 407219, ROC

Recruiting Trial

582Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1346Cases

2019-12-01 - 2022-12-20

Phase III

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

  • Condition/Disease

    Severe Vasomotor Symptoms (Hot Flashes)

  • Test Drug

    Fezolinetant

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated2Sites

2010-09-30 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-11-01 - 2018-10-20

Phase I/II

A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

  • Condition/Disease

    Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

  • Test Drug

    Lipotecan®; (TLC388 HCl for Injection)

Participate Sites
3Sites

Terminated3Sites

2016-12-01 - 2018-12-31

Phase II

A Phase IIa, Randomized, Double blinded, Placebo-controlled, Dose-finding Study for Single-dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee

  • Condition/Disease

    Osteoarthritis (OA) of Knee

  • Test Drug

    TLC599

Participate Sites
9Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

2016-01-01 - 2020-03-31

Phase IV

A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients with Peripheral T-cell Lymphoma after Prior Therapy

  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    FOLOTYN Solution for intravenous injection

Participate Sites
11Sites

Terminated11Sites

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

  • Condition/Disease

    Diabetic peripheral neuropathy pain

  • Test Drug

    DS-5565

Participate Sites
17Sites

Terminated17Sites

2015-03-01 - 2017-05-31

Phase III

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

  • Condition/Disease

    POST-HERPETIC NEURALGIA

  • Test Drug

    DS-5565

Participate Sites
14Sites

Terminated14Sites

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Test Drug

    DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅
Taipei Veterans General Hospital

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 123 124 125 126 127 135
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB